Cepheid Also to Host Integrated Symposium ‘The Medical & Public Health Impact of Rapid Molecular Testing’

SUNNYVALE, Calif.– Cepheid (NASDAQ: CPHD) will initiate European launch of its newest addition to the GeneXpert® family of molecular diagnostic testing systems, the GeneXpert Infinity-48, at the 20th annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Vienna, Austria. The GeneXpert Infinity-48 System is the world’s first and only fully-automated, random-access system designed for management of the entire molecular testing workflow — from sample data, cartridge loading and unloading, to final reporting of test results and disposal of cartridges.

“We’re very excited to be a part of the 20th anniversary of this renowned congress where we will officially debut our new GeneXpert Infinity-48 System in Europe,” said Nico Arnold, Executive Vice President of Worldwide Commercial Operations for Cepheid. “The GeneXpert family of Systems, including the Infinity-48, represents the next generation in automated molecular testing. With our expanding pipeline of rapid, accurate, and easy-to-use tests, the GeneXpert System is positioned to become the molecular platform of choice.”

Cepheid is also hosting an integrated symposium at the Congress, entitled The Medical and Public Health Impact of Rapid Molecular Testing. This will take place as part of the official program on Monday, April 12th, in Lecture Hall F2 from 9:00 a.m. -11:00 a.m. The schedule for the symposium is as follows:

The Medical and Public Health Impact of Rapid Molecular Testing

Cepheid Chair: Fred Tenover (Sunnyvale, US)

ECCMID Chair: Laurent Gutmann (Paris, FR)

At the hospital/community interface: Impact of molecular methods

9:00 on the diagnosis of respiratory tract infections

Greet Ieven (Antwerp, BE)

In the pharmacy: Optimizing antimicrobial stewardship and therapy

9:30 using a rapid MRSA/SA blood test

Debra Goff (Columbus, US)

In the maternity ward: Impact of universal intrapartum Group B

10:00 streptococcus screening using molecular diagnostics

Najoua El Helali (Paris, FR)

In the surgical unit: Improving patient safety by ignoring

10:30 resistance

Jan Kluytmans (Breda, NL)

The company will also be demonstrating the full menu of GeneXpert-based CE IVD molecular diagnostic tests at booth #261 on the exhibition floor, including:

— Xpert® Flu A Panel: Detection of FluA and identification of 2009 H1N1 novel

— Xpert® MTB/RIF: Simultaneous detection of Mycobacterium tuberculosis and resistance to rifampicin

— Xpert® C. difficile: Accurate detection of Clostridium difficile

infection

— Xpert® vanA/vanB: Screening for vancomycin-resistant enterococci (VRE)

— Xpert® MRSA: Screening for nasal carriage of Methicillin-Resistant Staphylococcus aureus

— Xpert® MRSA/SA BC: Diagnostic test for Methicillin-Resistant Staphylococcus aureus and S. aureus in positive patient blood culture bottles

— Xpert® MRSA/SA Nasal: Pre-Surgical testing for Staphylococcus aureus and Methicillin-Resistant S. aureus

— Xpert® MRSA/SA SSTI: Diagnostic test for Staphylococcus aureus and Methicillin-Resistant S. aureus in skin and soft tissue

— Xpert® EV: Rapid diagnostic test for enteroviral meningitis

— Xpert® GBS: Accurate and rapid detection of vaginal carriage of Group B

— Streptococcus

— Xpert® BCR-ABL Monitor: Simple and rapid monitoring test for improved

Chronic Myeloid Leukemia (CML) patient management

— Xpert® HemosIL FII & FV*: Detection of factor II and factor V Leiden

genetic variations associated with thrombophilia

About the GeneXpert Infinity-48 Molecular Diagnostic System

Cepheid’s GeneXpert Infinity-48 System, which uses robotic cartridge handling managed through a touch-screen driven menu, is capable of running a variety of molecular tests with a through-put capability of over 1,300 samples in a 24-hour period. With each of the system’s 48 testing modules working as completely independent testing sites, the Infinity-48 System can start test runs whenever samples are taken — 24 hours a day, 365 days a year. Delivering true walk away ease-of-use, the Infinity-48 System is designed to maximize workflow while further accelerating time-to-result, enabling healthcare providers to make more informed patient management and treatment decisions.

About Cepheid

Based in Sunnyvale, Calif., Cepheid (NASDAQ:CPHD) is an on-demand molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial and biothreat markets. The company’s systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The company’s easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. See https://www.cepheid.com/ for more information.

*Exclusively distributed by Instrumentation Laboratory